Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model

World Journal of Gastroenterology

Volumn 17, Issue 44, 2011, Pages 4858-4866

  Pagán, Beatriz ^a   Isidro, Angel A ^a   Cruz, Myrella L ^a   Ren, Yuan ^b   Coppola, Domenico ^b   Wu, Jie ^b   Appleyard, Caroline B ^a  

^a PONCE SCHOOL OF MEDICINE   (Puerto Rico)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Animal model; Colitis; Dysplasia; Epidermal growth factor receptor; Erlotinib

Indexed keywords

ALCOHOL; ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; COLITIS; COLON CANCER; COLON MUCOSA; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIUM CELL; GASTROINTESTINAL DYSPLASIA; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

EID: 83155177151     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i44.4858     Document Type: Article

References (25)

1. Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138: 746-774, 774.e1-4; quiz e2-3
2. Solomon MJ, Schnitzler M. Cancer and inflammatory bowel disease: bias, epidemiology, surveillance, and treatment. World J Surg 1998; 22: 352-358
3. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010; 7: 493-507
4. Lurje G, Lenz HJ. EGFR signaling and drug discovery. Oncology 2009; 77: 400-410
5. Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 2009; 20: 851-855
6. Castagliuolo I, Morteau O, Keates AC, Valenick L, Wang CC, Zacks J, Lu B, Gerard NP, Pothoulakis C. Protective effects of neurokinin-1 receptor during colitis in mice: role of the epidermal growth factor receptor. Br J Pharmacol 2002; 136: 271-279
7. Svrcek M, El-Bchiri J, Chalastanis A, Capel E, Dumont S, Buhard O, Oliveira C, Seruca R, Bossard C, Mosnier JF, Berger F, Leteurtre E, Lavergne-Slove A, Chenard MP, Hamelin R, Cosnes J, Beaugerie L, Tiret E, Duval A, Fléjou JF. Specific clinical and biological features characterize inflammatory bowel disease associated colorectal cancers showing microsatellite instability. J Clin Oncol 2007; 25: 4231-4238
8. Navolanic PM, Steelman LS, McCubrey JA. EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). Int J Oncol 2003; 22: 237-252
9. Trzcinski R, Bry M, Krajewska W, Kulig M, Dzyiki A. ErbB-1 expression in experimental model of inflammatory bowel disease in rats. Acta Chir Iugosl 2004; 51: 85-89
10. Malecka-Panas E, Kordek R, Biernat W, Tureaud J, Liberski PP, Majumdar AP. Differential activation of total and EGF receptor (EGF-R) tyrosine kinase (tyr-k) in the rectal mucosa in patients with adenomatous polyps, ulcerative colitis and colon cancer. Hepatogastroenterology 1997; 44: 435-440
11. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995; 109: 1344-1367
12. Dougherty U, Sehdev A, Cerda S, Mustafi R, Little N, Yuan W, Jagadeeswaran S, Chumsangsri A, Delgado J, Tretiakova M, Joseph L, Hart J, Cohen EE, Aluri L, Fichera A, Bissonnette M. Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model. Clin Cancer Res 2008; 14: 2253-2262
13. Santiago C, Pagán B, Isidro AA, Appleyard CB. Prolonged chronic inflammation progresses to dysplasia in a novel rat model of colitis-associated colon cancer. Cancer Res 2007; 67: 10766-10773
14. Appleyard CB, Wallace JL. Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs. Am J Physiol 1995; 269: G119-G125
15. Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA, Vaidya MP, Arnold LD, Doty JL, Iwata KK, Morin MJ. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999; 291: 739-748
16. Pagán B, Isidro AA, Coppola D, Chen Z, Ren Y, Wu J, Appleyard CB. Effect of a neurokinin-1 receptor antagonist in a rat model of colitis-associated colon cancer. Anticancer Res 2010; 30: 3345-3353
17. Fenoglio-Preiser CM, Noffsinger AE, Stemmermann GN, Lantz PE, Listrom MB and Rilke FO. Inflammatory bowel disease. In: Gastrointestinal Pathology, an Atlas and Text. 2nd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 1999: 631-716
18. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200-206
19. Chen L, Pernazza D, Scott LM, Lawrence HR, Ren Y, Luo Y, Wu X, Sung SS, Guida WC, Sebti SM, Lawrence NJ, Wu J. Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112. Biochem Pharmacol 2010; 80: 801-810
20. Mercier S, Breuillé D, Mosoni L, Obled C, Patureau Mirand P. Chronic inflammation alters protein metabolism in several organs of adult rats. J Nutr 2002; 132: 1921-1928
21. Egger B, Tolmos J, Procaccino F, Sarosi I, Friess H, Büchler MW, Stamos M, Eysselein VE. Keratinocyte growth factor promotes healing of left-sided colon anastomoses. Am J Surg 1998; 176: 18-24
22. Procaccino F, Reinshagen M, Hoffmann P, Zeeh JM, Lakshmanan J, McRoberts JA, Patel A, French S, Eysselein VE. Protective effect of epidermal growth factor in an experimental model of colitis in rats. Gastroenterology 1994; 107: 12-17
23. Köhne CH, Lenz HJ. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist 2009; 14: 478-488
24. Niederle N, Freier W, Porschen R. Erlotinib as single agent in 2nd and 3rd line treatment in patients with metastatic colorectal cancer. Results of a two-cohort multicenter phase II trial. Eur J Cancer 2005; 3 Suppl, 184 Poster 649
25. Townsley CA, Major P, Siu LL, Dancey J, Chen E, Pond GR, Nicklee T, Ho J, Hedley D, Tsao M, Moore MJ, Oza AM. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer 2006; 94: 1136-1143